Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
National Institutes of Health (NIH)
Estimated funding amount: $150,000 per application
Project duration: Up to 2 years
Encourage revision applications from currently funded NCI R01 research projects.
Expand original research questions or accelerate progress by incorporating new technical approaches or devices.
Researchers in cancer studies
Broader cancer research community
Patients benefiting from improved cancer research outcomes
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Organizations must be currently funded NCI R01 awardees to apply.
Eligible organizations can be based in the U.S. or be foreign organizations.
Non-domestic (non-U.S.) components of U.S. organizations are also eligible.
Projects must propose to incorporate new technologies developed through the NCI IMAT program.
Applications should aim to enhance the parent research study.
Application budgets may not exceed $150,000 in direct costs per year.
No cost sharing is required.
Application due date: October 3, 2025.
Open date for submissions: March 4, 2025.
Applicants may submit more than one application as long as each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Specific forms and templates must be used as outlined in the application guide.
Applications will be evaluated based on scientific merit, innovation, and feasibility.
Applications will undergo peer review by appropriate Scientific Review Groups.
Scientific and technical merit of the proposed project will be the primary selection criterion.
Applications must propose to incorporate technology platforms developed through the NCI IMAT program.
Applications proposing to use commercially available technologies will not be considered.
Demonstrating the readiness of the proposed technology for independent validation.
Submitting applications that overlap with previously submitted proposals.
Engage with the Scientific/Research Contact for assistance in finding suitable technology platforms.